« Previous
Next »
Experimental Hematology
Volume 36, Issue 5
, Pages 533-534
, May 2008
Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases
References
- . The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17:282–289
- APRIL promotes B-1 cell-associated neoplasm. Cancer Cell. 2004;6:399–408
- . Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun. 2005;8:266–288
- . APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica. 2007;92:1284–1285
- Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood. 2007;109:331–338
- Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109:729–739
- Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol. 2005;18:90–96
- Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia. 2007;21:1324–1327
- . Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease. J Cancer Res Clin Oncol. 1985;110:65–70
PII: S0301-472X(08)00004-0
doi: 10.1016/j.exphem.2007.12.017
© 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Experimental Hematology
Volume 36, Issue 5
, Pages 533-534
, May 2008
